This World Cancer Day (4 February 2026), we take a look at some recent drug discovery developments with the potential to transform the oncology pharma landscape. Cancer remains a leading cause of mortality worldwide, with legions of scientists dedicating their research efforts toward the development of novel and effective therapeutics. We have seen substantial advances over the years, including but not limited to personalized immunotherapies, cell, gene and mRNA-based therapies for certain cancers and novel drug delivery systems, and the breakthroughs show no sign of slowing down any time soon. Here, we highlight four recent preclinical advances in the cancer research drug discovery space of particular note, which address some of the biggest challenges in this area and offer hope for future treatments for a number of different cancers. Fungal compound with promise for treating brain cancer synthesized A collaborative team from Massachusetts Institute of Technology and the Dana-Farber Cancer Institute, Harvard Medical School (both MA, USA) has, for the first time, succeeded in synthesizing the fungal metabolite verticillin A, demonstrating that derivatives of the compound appear to combat a type of pediatric brain cancer called diffuse midline glioma. Verticillin A was discovered over 50 years ago and has shown promise as an anticancer agent in the decades since. However, its complex structure has meant that it is difficult to synthesize, and so has yet to live up to its potential. Now, researchers have reported the first total synthesis of verticillin A, outlining a 16-step protocol that begins with the…
